Dr. Gordon Mills, MD
Dr. Gordon Mills, MD is a gynecologist oncologist in Houston, TX and has over 45 years of experience in the medical field. He graduated from University of Alberta in 1977.
Practice
1515 Holcombe Blvd Houston, TX 77030Compare with other Gynecologist Oncologists
Compare Dr. Mills with our nearby Gynecologist Oncologists at HCA Houston Healthcare Medical Center.
Make an appointment at HCA Houston Healthcare Medical Center today at
(713) 352-2952.
Experience Check
Search for experience in a specific area
Dr. Mills' Reviews
Overall Patient Satisfaction
About Me
biography
Dr. Gordon Mills, MD is a gynecologist oncologist in Houston, TX and has over 45 years of experience in the medical field. He graduated from University of Alberta in 1977.Gynecologic Oncology
*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.
University Of Alberta
Medical School, 1977
Healthgrades receives board action history for physicians and physician assistants. The information displayed here is sourced from independent information providers, such as state board websites, and may not be the most up-to-date information. Healthgrades makes no representations with respect to the accuracy of any information provided here and assumes no responsibility or liability for such information.
Learn more about medical license public record checkComprehensive Characterization of Cancer Driver Genes and Mutations, 2018-04-05
Unraveling the regulatory connections between two controllers of breast cancer cell fate, 2014-05-03
Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy, 2012-12-05
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype, 2018-05-03
Abortive Autophagy Induces Endoplasmic Reticulum Stress and Cell Death in Cancer Cells, 2012-06-26
Functional consequence of theMET-T1010I polymorphism in breast cancer, 2014-12-31
Next-generation characterization of the Cancer Cell Line Encyclopedia, 2019-05-08
Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer, 2016-10-24
Comprehensive molecular characterization of gastric adenocarcinoma, 2014-07-23
TransVar: a trans-level variant annotator for precision genomics, 2016-02-22
A unified approach to targeting the lysosome's degradative and growth signaling roles, 2017-09-12
Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function, 2016-03-14
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer, 2012-08-29
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers, 2015-10-01
PRECISION ONCOLOGY DECISION SUPPORT: CURRENT APPROACHES AND STRATEGIES FOR THE FUTURE, 2018-02-02
Survival Outcomes byTP53Mutation Status in Metastatic Breast Cancer, 2018-04-25
Concordance of Genomic Alterations Between Primary and Recurrent Breast Cancer, 2014-03-07
"Personalized Cancer Therapy”: A Publically Available Precision Oncology Resource, 2017-11-01
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer, 2018-10-30
Assessing the clinical utility of cancer genomic and proteomic data across tumor types, 2014-06-22
PKC iota promotes ovarian tumor progression through deregulation of cyclin E, 2015-08-17
Genome-wide Transcriptome Profiling of Homologous Recombination DNA Repair, 2014-04-19
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer, 2020-04-14
Comprehensive molecular characterization of muscle invasive bladder cancer, 2017-10-05
AMPK Signaling Results in Cytoplasmic Sequestration of p27, 2008-08-15
Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps, 2014-08-20
PTK6 Regulates IGF-1-Induced Anchorage-Independent Survival, 2010-07-23
Physician Interpretation of Genomic Test Results and Treatment Selection, 2017-11-22
Rab11-FIP1C is a critical negative regulator in ErbB2-mediated mammary tumor progression, 2016-03-01
Breast cancer quantitative proteome and proteogenomic landscape, 2019-04-08
Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors, 2013-02-21
Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents, 2012-08-21
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer, 2011-04-13
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers, 2011-02-15
Site Specific Activation of AKT Protects Cells from Death Induced by Glucose Deprivation, 2013-02-11
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer, 2013-01-15
EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation, 2018-04-19
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer, 2018-04-26
Predicting high-risk endometrioid carcinomas using proteins, 2018-04-13
RNA editing derived epitopes function as cancer antigens to elicit immune responses, 2018-09-25
AKT isoform-specific expression and activation across cancer lineages, 2018-07-16
Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis, 2015-12-10
Prognostic relevance of acquired uniparental disomy in serous ovarian cancer, 2015-02-03
Multilevel Genomics-based Taxonomy of Renal Cell Carcinoma, 2016-03-03
Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation, 2018-06-22
Systematic Functional Annotation of Somatic Mutations in Cancer, 2018-03-12
Clinical outcomes based on multigene profiling in metastatic breast cancer patients, 2016-10-28
Mask is required for the activity of the Hippo pathway effector Yki/YAP, 2013-01-17
BRD4 facilitates replication stress-induced DNA damage response, 2018-04-11
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics, 2018-04-05
State-of-the-art strategies for targeting the DNA damage response in cancer, 2021-07-26
Surviving ovarian cancer: an affair between defective DNA repair and RB1, 2017-11-30
Clinical actionability enhanced through deep targeted sequencing of solid tumors, 2015-01-27
Characterization of Human Cancer Cell Lines by Reverse-Phase Protein Arrays, 2017-02-13
Detection Algorithm for the Validation of Human Cell Lines, 2012-04-12
Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules, 2013-08-05
Integrated Molecular Characterization of Uterine Carcinosarcoma, 2017-03-13
Clinical Use of Precision Oncology Decision Support, 2017-09-13
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations, 2017-05-18
A pan-cancer proteomic perspective on The Cancer Genome Atlas, 2014-05-29
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma, 2018-04-03
Cancer Systems Biology: a peak into the future of patient care?, 2014-02-04
Neomorphic mutations create therapeutic challenges in cancer, 2016-11-14
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer, 2011-05-13
Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer, 2014-06-03
Mouse models of humanPIK3CA-related brain overgrowth have acutely treatable epilepsy, 2015-12-03
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma, 2018-03-21
Molecular determinants of post-mastectomy breast cancer recurrence, 2018-10-12
Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis, 2014-07-07
In vivo screening identifiesGATAD2Bas a metastasis driver inKRAS-driven lung cancer, 2018-07-16
Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-?B Pathway in Melanoma, 2017-04-07
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma, 2017-08-14
Clinical relevance ofTP53hotspot mutations in high-grade serous ovarian cancers, 2019-11-29
Comprehensive Genomic Characterization of Long Non-Coding RNAs across Human Cancers, 2015-10-12
ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma, 2017-09-08
A comprehensive Pan-Cancer molecular study of gynecologic and breast cancers, 2018-04-02
Oncogenic RAS regulates long non-coding RNAOrilnc1in human cancer, 2017-05-04
Focus on Breast Cancer
Insurance Check
Search for your insurance carrier and choose your plan type
Locations
Practice
- Call
- Fax
- Hours
- Mon: closed
- Tue: closed
- Wed: 7:00am - 4:00pm
- Thu: closed
- Fri: 7:00am - 1:00pm
- Sat: closed
- Sun: closed
- Directions
Compare with other Gynecologist Oncologists
Compare Dr. Mills with our nearby Gynecologist Oncologists at HCA Houston Healthcare Medical Center.
Make an appointment at HCA Houston Healthcare Medical Center today at
(713) 352-2952.